{
    "name": "plerixafor",
    "comment": "Rx",
    "other_names": [
        "Mozobil"
    ],
    "classes": [
        "Hematopoietic Stem Cell Mobilizers"
    ],
    "source": "https://reference.medscape.com/drug/mozobil-plerixafor-342168",
    "pregnancy": {
        "common": [
            "Limited available data in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes",
            "Advise pregnant women of potential risk to fetus",
            "Advise women of reproductive potential to avoid becoming pregnant while receiving treatment",
            "Verify pregnancy status in females of reproductive potential prior to initiating therapy",
            "Therapy can cause embryo-fetal harm when administered to pregnant women; advise females of reproductive potential to use effective contraception during treatment and for one week after final dose"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, subcutaneous administration of plerixafor to pregnant rats during organogenesis at doses ten times maximum recommended human doses resulted in embryo-fetal mortality, structural abnormalities, and alterations to growth"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of plerixafor in human milk, effect on breastfed child, or the effect on milk production; because of potential serious adverse reactions in breastfed child, advise females that breastfeeding is not recommended during treatment and for one week after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None listed in the manufacturer's labeling",
                "History of hypersensitivity; anaphylaxis reported"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not intended for HSC mobilization and harvest in patients with leukemia",
                "When used in combination with filgrastim tumor cells may be released from the bond marrow and subsequently collected in the leukapheresis product. Effects of potential reinfusion of tumor cells not studied",
                "Dose reduction recommended in patients with moderate-severe renal impairment",
                "Leukocytosis; use in conjunction with G-CSF increases circulating leukocytes as well as HSC populations",
                "Risk of thrombocytopenia; monitor platelet counts in all patients receiving treatment and then undergo apheresis",
                "Risk of splenic enlargement and rupture",
                "Optimal effective dose in patients wighing >175% of ideal body weight not studied",
                "Cases of splenic enlargement and/or rupture reported following administration in conjunction with growth factor G-CSF",
                "Medications that reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "37"
        },
        {
            "name": "Injection site reaction",
            "percent": "34"
        },
        {
            "name": "Nausea",
            "percent": "34"
        },
        {
            "name": "Fatigue",
            "percent": "27"
        },
        {
            "name": "Headache",
            "percent": "22"
        },
        {
            "name": "Arthralgia",
            "percent": "13"
        },
        {
            "name": "Dizziness",
            "percent": "11"
        },
        {
            "name": "Vomiting",
            "percent": "10"
        },
        {
            "name": "Insomnia",
            "percent": "7"
        },
        {
            "name": "Flatulence",
            "percent": "7"
        },
        {
            "name": "Vomiting",
            "percent": "10"
        },
        {
            "name": "Immune System Disorders",
            "percent": null
        },
        {
            "name": "Anaphylactic reactions",
            "percent": null
        },
        {
            "name": "including anaphylactic shock",
            "percent": null
        },
        {
            "name": "Abnormal dreams and nightmares",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system",
            "percent": null
        },
        {
            "name": "Splenomegaly and splenic rupture",
            "percent": null
        }
    ]
}